CY1114544T1 - Παραγωγα πληρως ν-αποθειωμενων γλυκοζαμινογλυκανων ως αναστολεις ηπαρανασης, τα οποια διαθετουν αντιαγγειογονικη δραστικοτητα και δεν επιφερουν αντιθρομβωτικο αποτελεσμα - Google Patents

Παραγωγα πληρως ν-αποθειωμενων γλυκοζαμινογλυκανων ως αναστολεις ηπαρανασης, τα οποια διαθετουν αντιαγγειογονικη δραστικοτητα και δεν επιφερουν αντιθρομβωτικο αποτελεσμα

Info

Publication number
CY1114544T1
CY1114544T1 CY20131100685T CY131100685T CY1114544T1 CY 1114544 T1 CY1114544 T1 CY 1114544T1 CY 20131100685 T CY20131100685 T CY 20131100685T CY 131100685 T CY131100685 T CY 131100685T CY 1114544 T1 CY1114544 T1 CY 1114544T1
Authority
CY
Cyprus
Prior art keywords
activity
fully
derivatives
glycosymin
glycans
Prior art date
Application number
CY20131100685T
Other languages
English (en)
Inventor
Benito Casu
Giangiacomo Torri
Annamaria Naggi
Giuseppe Giannini
Claudio Pisano
Sergio Penco
Original Assignee
Sigma-Tau Research Switzerland S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Research Switzerland S.A. filed Critical Sigma-Tau Research Switzerland S.A.
Publication of CY1114544T1 publication Critical patent/CY1114544T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Abstract

Αποκαλύπτονται πλήρως αποθειωμένα, Ν-επανακετυλιωμένα παράγωγα ηπαρίνης τα οποία διαθέτουν αντιαγγειογονική και δεν διαθέτουν αντιθρομβωτική δραστικότητα.
CY20131100685T 2001-09-12 2013-08-09 Παραγωγα πληρως ν-αποθειωμενων γλυκοζαμινογλυκανων ως αναστολεις ηπαρανασης, τα οποια διαθετουν αντιαγγειογονικη δραστικοτητα και δεν επιφερουν αντιθρομβωτικο αποτελεσμα CY1114544T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10183832.4A EP2343077B1 (en) 2001-09-12 2001-09-12 Derivatives of totally N-desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
PCT/IT2001/000472 WO2003022291A1 (en) 2001-09-12 2001-09-12 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect

Publications (1)

Publication Number Publication Date
CY1114544T1 true CY1114544T1 (el) 2016-10-05

Family

ID=11133723

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100823T CY1112551T1 (el) 2001-09-12 2011-08-29 Παραγωγα μερικως αποσουλφωμενων γλυκοζαμινογλυκανων ως αναστολεις ηπαρανασης, τα οποια διαθετουν αντιαγγειογονο δραστικοτητα και στερουνται αντιπηκτικης επιδρασης
CY20131100685T CY1114544T1 (el) 2001-09-12 2013-08-09 Παραγωγα πληρως ν-αποθειωμενων γλυκοζαμινογλυκανων ως αναστολεις ηπαρανασης, τα οποια διαθετουν αντιαγγειογονικη δραστικοτητα και δεν επιφερουν αντιθρομβωτικο αποτελεσμα

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20111100823T CY1112551T1 (el) 2001-09-12 2011-08-29 Παραγωγα μερικως αποσουλφωμενων γλυκοζαμινογλυκανων ως αναστολεις ηπαρανασης, τα οποια διαθετουν αντιαγγειογονο δραστικοτητα και στερουνται αντιπηκτικης επιδρασης

Country Status (20)

Country Link
US (1) US20050137167A1 (el)
EP (2) EP2343077B1 (el)
JP (1) JP2005506326A (el)
KR (1) KR100855331B1 (el)
CN (1) CN1547477B (el)
AT (1) ATE511846T1 (el)
AU (1) AU2001292231B2 (el)
BR (1) BR0117124A (el)
CA (1) CA2457719C (el)
CY (2) CY1112551T1 (el)
CZ (1) CZ307433B6 (el)
DK (1) DK1427427T3 (el)
ES (2) ES2431362T3 (el)
HK (1) HK1069537A1 (el)
HU (1) HU230385B1 (el)
MX (1) MXPA04002217A (el)
PT (2) PT2343077E (el)
SI (1) SI1427427T1 (el)
SK (1) SK288335B6 (el)
WO (1) WO2003022291A1 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1731131A1 (en) * 2004-03-29 2006-12-13 Kringle Pharma Inc. Hgf production accelerator containing heparin-like oligosaccharide
EP2086553A4 (en) * 2006-10-20 2010-12-29 Univ Australian INHIBITION OF EXTRACELLULAR MATRIX DEGRADATION
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
EP2205642B1 (en) 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
FI20085308A0 (fi) * 2008-04-11 2008-04-11 Polysackaridforskning I Uppsal Heparanaasittomia ihmiskuntaan kuulumattomia nisäkkäitä
FR2949115B1 (fr) * 2009-08-14 2012-11-02 Sanofi Aventis OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
AU2011226755A1 (en) * 2010-03-12 2012-10-04 The Australian National University Heparan sulfate replacement therapy
WO2011130697A2 (en) 2010-04-16 2011-10-20 Momenta Pharmaceuticals, Inc. Tissue targeting
CN103096870B (zh) 2010-06-17 2017-04-19 动量制药公司 调节毛发生长的方法和组合物
FR2970969B1 (fr) * 2011-01-27 2013-10-18 Sanofi Aventis Oligosaccharides 3-o-alkyles activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique
KR101522604B1 (ko) * 2013-03-21 2015-05-26 대한민국 곤충 글라이코자미노글라이칸 유래 헤파린 단편 및 이의 제조 방법
CN105408361B (zh) * 2013-05-16 2019-09-06 新加坡科技研究局 硫酸乙酰肝素
CA2910837A1 (en) 2013-05-28 2014-12-04 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
ITLO20130005A1 (it) * 2013-10-31 2015-05-01 He E Biochimiche G Ronzonr S R Derivati di glucosamminoglicani n-desolfatati e loro uso come farmaci
ITLO20130006A1 (it) * 2013-11-06 2015-05-07 He E Biochimiche G Ronzoni S R Derivati carbossilati di glucosamminoglicani e loro uso come farmaci
HUE042681T2 (hu) 2015-03-06 2019-07-29 Leadiant Biosciences Sa In Liquidazione Myeloma multiplex roneparstat kombinációs terápiája
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
JP2020503377A (ja) 2016-12-13 2020-01-30 ベータ セラピューティクス プロプライアタリー リミティド ヘパラナーゼ阻害剤及びそれの使用
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
EP3601312A4 (en) * 2017-03-23 2020-12-23 Victoria Link Limited GLYCOMIMETIC COMPOUNDS OF HEPARAN SULPHATE AND THEIR PHARMACEUTICAL AND COSMETIC USES
EP3388439A1 (en) 2017-04-11 2018-10-17 Leadiant Biosciences SA Biotin-conjugated n-acetyl glycol split heparin
WO2019149179A1 (zh) * 2018-02-02 2019-08-08 深圳市海普瑞药业集团股份有限公司 糖胺聚糖衍生物及其制备方法和用途
EP3705126A1 (en) 2019-03-05 2020-09-09 Leadiant Biosciences S.p.A. Roneparstat for the treatment of amyloidosis
WO2021128253A1 (zh) * 2019-12-27 2021-07-01 深圳市海普瑞药业集团股份有限公司 一种糖胺聚糖衍生物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265998A (ja) * 1986-03-10 1987-11-18 ボ−ド　オブ　リ−ジエンツ　ザ　ユニヴア−シテイ　オブ　テキサス　システム ヘパラン硫酸エンドグリコシダーゼアッセイ
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
IE61758B1 (en) 1986-05-23 1994-11-30 Daiichi Seiyaku Co Use of a sulfated polysaccharide
IL79254A0 (en) 1986-06-26 1986-09-30 Hadassah Med Org Compositions for preventing graft rejection
IL79255A0 (en) * 1986-06-26 1986-09-30 Hadassah Med Org Composition for metastasis prevention
AU7852687A (en) * 1986-08-21 1988-03-08 University Of Texas System, The Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness or metastatic profusion
IL85145A (en) 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
CZ195193A3 (en) 1992-09-25 1994-04-13 Lilly Co Eli Modified factor-4 of blood platelets, process of its preparation and pharmaceutical preparation in which it is comprised
US5296471A (en) * 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
US5696100A (en) 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US5399667A (en) 1993-03-05 1995-03-21 Washington University Thrombospondin receptor binding peptides
IT1264101B1 (it) 1993-03-29 1996-09-10 Alfa Wassermann Spa Processo per la sintesi di glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2
IT1264709B1 (it) * 1993-07-12 1996-10-04 Italfarmaco Spa Derivati eparinici ad attivita' antimetastatica
AU7520394A (en) 1993-08-13 1995-03-14 Glycomed Incorporated Bridged oligosaccharides and sulfated derivatives thereof
US5739115A (en) 1993-10-07 1998-04-14 Glycomed Incorporated Sulfated maltooligosaccharides with heparin-like properties
JPH09503510A (ja) 1993-10-07 1997-04-08 グリコメド・インコーポレイテッド ヘパリン様特性を有する高硫酸化マルトオリゴ糖
AU2435795A (en) 1994-05-06 1995-11-29 Glycomed Incorporated O-desulfated heparin derivatives, methods of making and uses thereof
AUPN261895A0 (en) 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
JP4051099B2 (ja) * 1997-01-31 2008-02-20 生化学工業株式会社 低分子化ヘパリン、その製造法及び医薬組成物
DE19955803A1 (de) 1999-11-19 2001-05-23 Knoll Ag Verwendung von Heparanase-Inhibitoren zur Behandlung von Hersinsuffizienz
AU3078800A (en) * 2000-01-25 2001-08-07 Nippon Eisei Center Co., Ltd. Earthquake-proofing reinforcing metal fitting
IT1316986B1 (it) * 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.

Also Published As

Publication number Publication date
HU230385B1 (hu) 2016-03-29
SK1602004A3 (en) 2004-08-03
DK1427427T3 (da) 2011-09-19
CN1547477A (zh) 2004-11-17
KR20040048404A (ko) 2004-06-09
PT2343077E (pt) 2013-08-29
SK288335B6 (sk) 2016-02-02
KR100855331B1 (ko) 2008-09-04
JP2005506326A (ja) 2005-03-03
CY1112551T1 (el) 2016-02-10
EP2343077A1 (en) 2011-07-13
CA2457719A1 (en) 2003-03-20
ES2431362T3 (es) 2013-11-26
EP1427427B1 (en) 2011-06-08
ATE511846T1 (de) 2011-06-15
HUP0401693A3 (en) 2009-06-29
AU2001292231B2 (en) 2008-06-05
CA2457719C (en) 2012-01-03
US20050137167A1 (en) 2005-06-23
HUP0401693A2 (hu) 2004-12-28
MXPA04002217A (es) 2004-07-08
PT1427427E (pt) 2011-09-13
EP1427427A1 (en) 2004-06-16
BR0117124A (pt) 2004-09-28
EP2343077B1 (en) 2013-07-17
CZ307433B6 (cs) 2018-08-22
HK1069537A1 (en) 2005-05-27
ES2367778T3 (es) 2011-11-08
CZ2004255A3 (cs) 2004-11-10
CN1547477B (zh) 2010-12-22
WO2003022291A1 (en) 2003-03-20
SI1427427T1 (sl) 2011-10-28

Similar Documents

Publication Publication Date Title
CY1114544T1 (el) Παραγωγα πληρως ν-αποθειωμενων γλυκοζαμινογλυκανων ως αναστολεις ηπαρανασης, τα οποια διαθετουν αντιαγγειογονικη δραστικοτητα και δεν επιφερουν αντιθρομβωτικο αποτελεσμα
LTPA2019511I1 (lt) Rapamicino darinys, skirtas plaučių vėžio gydymui
DK1420801T3 (da) Anvendelse af fucaner til behandling af adhæsioner, arthritis og psoreasis
CY1107174T1 (el) Συνδυασμοι εζετιμιβε με ασπιρινη για θεραπεια αγγειακων καταστασεων
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
EA200601124A1 (ru) Противовирусные фармацевтические композиции
ATE554114T1 (de) Copolymer mit zwitterionischen einheiten und anderen einheiten, das copolymer umfassende zusammensetzung und verwendung
BRPI0412404A (pt) uso de rapamicina e de derivado da rapamicina para o tratamento da perda óssea
MY136892A (en) Deacetylase inhibitors
TW200420573A (en) Bifunctional heterocyclic compounds and methods of making and using same
BR0214750A (pt) Imidazoquinolinas tioéter substituìdas
WO2003005999A3 (en) Methods of treating cytokine mediated diseases
WO2003059296A3 (en) Compositions comprising collagen and metalloprotease inhibitors
TR200103575T2 (tr) Sülfonamid ve sülfamid ikameli/katkılı imidazokinolinler
NO20034094L (no) Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat
EA200301091A1 (ru) Противоопухолевые комбинации, такие как рапамицин вместе с гемцитабином или фторурацилом
ATE305932T1 (de) Rapanycin29-enole
BR0316170A (pt) Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer
DE60221247D1 (de) Schweisshemmende oder deodorierende zusammensetzungen
ATE348115T1 (de) Teildesulfatierte glykosaminoglykanderivate mit antiangiogenischer aktivität und ohne antikoagulierender wirkung
UA86042C2 (en) Substituted indazole-o-glucosides
SE0101932D0 (sv) Pharmaceutical combinations
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
FR2842103B1 (fr) Nouvelles applications cosmetiques de polyphenoles et de leurs derives
DK1362045T3 (da) 2-Thio-substituerede imidazolderivater og deres anvendelse inden for farmacien